Dr. Usmani Discusses Management of Early Relapse in Myeloma

Saad Z. Usmani, MD, FACP
Published: Saturday, Mar 02, 2019



Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder,  director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, shares his advice for the management of early relapse in patients with multiple myeloma.

According to Usmani, one approach to this situation is not appropriate for all patients. Physicians should consider each regimen that could potentially be used for first relapse to decide which option is best for an individual patient. If there are 2 regimens with similar benefit, convenience for the patient should also be considered.

<<< 2019 International Congress on Hematologic Malignancies


Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder,  director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, shares his advice for the management of early relapse in patients with multiple myeloma.

According to Usmani, one approach to this situation is not appropriate for all patients. Physicians should consider each regimen that could potentially be used for first relapse to decide which option is best for an individual patient. If there are 2 regimens with similar benefit, convenience for the patient should also be considered.

<<< 2019 International Congress on Hematologic Malignancies

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x